The RemeOs Spinal Interbody Cage aims to re-establish the height between vertebrae and promote fusion within the cervical spine. Credit: Olena Yakobchuk/ Shutterstock.

Bioretec has announced an acceleration in the development of the RemeOs Spinal Interbody Cage, a medical device that is set to innovate spinal surgery with its MRI-compatible, absorbable hybrid composite technology.

This strategic decision follows the device’s receipt of the breakthrough device designation from the US Food and Drug Administration in March 2024.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This approval has led the company to re-evaluate its product development timeline and financial strategy, considering the device’s potential impact on spinal surgery technology.

The RemeOs Spinal Interbody Cage is designed to restore intervertebral height and facilitate fusion in the cervical spine. It stands out for its use of a magnesium alloy, which has earned patents in both the US (US11969519B1) and Europe (EP3782657B1).

It aims to overcome the limitations of traditional implants by reducing complications and improving patient outcomes.

The results from initial simulations and technological proofs of concept have established a strong commercial rationale for the acceleration of the RemeOs Spinal Interbody Cage’s development.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The feedback from medical experts has been positive, highlighting the device’s potential applications and benefits.

With an estimated market potential of approximately €2.3bn ($2.5bn) by 2028 for the RemeOs Spinal Interbody Cage and €8.1bn for related hybrid composite applications, Bioretec is positioning itself for a significant commercial opportunity.

The device’s properties are expected to enhance bone growth and reduce stress shielding complications.

To align with the revised product development strategy, Bioretec’s board of directors has updated the company’s financial targets.

Bioretec is exploring various financing options and has appointed Danske Bank, Finland Branch, as its financial advisor to support these efforts.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact